Analysts Set Expectations for SLDB Q1 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Stock analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Solid Biosciences in a report released on Friday, May 16th. William Blair analyst S. Corwin expects that the company will post earnings of ($0.54) per share for the quarter. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. William Blair also issued estimates for Solid Biosciences' Q2 2026 earnings at ($0.54) EPS.

SLDB has been the subject of several other reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $16.00 target price on shares of Solid Biosciences in a research note on Thursday. Barclays dropped their target price on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Piper Sandler dropped their target price on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Wedbush dropped their target price on Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, May 16th. Finally, HC Wainwright upped their target price on Solid Biosciences from $16.00 to $20.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Ten investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $14.90.

Solid Biosciences Stock Performance

Solid Biosciences stock traded down $0.08 during trading on Monday, hitting $2.81. The company's stock had a trading volume of 871,960 shares, compared to its average volume of 1,072,215. The stock has a market capitalization of $217.82 million, a price-to-earnings ratio of -0.92 and a beta of 2.32. The stock's fifty day moving average is $3.28 and its 200 day moving average is $4.12. Solid Biosciences has a 1-year low of $2.41 and a 1-year high of $10.37.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06).

Institutional Trading of Solid Biosciences

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in Solid Biosciences by 9,393.8% in the 4th quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company's stock worth $3,824,000 after acquiring an additional 945,863 shares during the period. Renaissance Technologies LLC raised its position in shares of Solid Biosciences by 12.7% in the 4th quarter. Renaissance Technologies LLC now owns 82,493 shares of the company's stock valued at $330,000 after purchasing an additional 9,281 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Solid Biosciences by 4.0% in the 4th quarter. Wellington Management Group LLP now owns 124,551 shares of the company's stock valued at $498,000 after purchasing an additional 4,747 shares in the last quarter. Rhumbline Advisers raised its position in shares of Solid Biosciences by 10.5% in the 4th quarter. Rhumbline Advisers now owns 43,677 shares of the company's stock valued at $175,000 after purchasing an additional 4,161 shares in the last quarter. Finally, Prudential Financial Inc. raised its position in shares of Solid Biosciences by 71.3% during the 4th quarter. Prudential Financial Inc. now owns 109,105 shares of the company's stock valued at $436,000 after acquiring an additional 45,400 shares in the last quarter. Hedge funds and other institutional investors own 81.46% of the company's stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.